Loading...
XNAS
GERN
Market cap987mUSD
Jun 16, Last price  
1.55USD
1D
2.65%
1Q
-10.40%
Jan 2017
-25.12%
Name

Geron Corp

Chart & Performance

D1W1MN
XNAS:GERN chart
P/E
—
P/S
12.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.71%
Rev. gr., 5y
178.45%
Revenues
77m
+32,386.92%
290,0003,277,0007,622,0002,803,0001,726,0003,563,0002,438,0002,709,0001,283,0001,153,00036,371,0006,162,0001,065,0001,066,000460,000253,0001,393,000596,000237,00076,994,000
Net income
-175m
L-5.19%
-33,528,000-31,365,000-36,697,000-62,021,000-70,184,000-111,377,000-96,853,000-68,881,000-38,379,000-35,670,00046,000-29,537,000-27,916,000-27,017,000-63,551,000-75,610,000-120,952,000-141,033,000-184,127,000-174,572,000
CFO
-219m
L+30.33%
-20,613,000-26,379,000-26,632,000-41,985,000-43,374,000-44,292,000-62,392,000-55,146,000-36,680,0009,350,000-24,196,000-18,369,000-20,556,000-21,009,000-43,829,000-66,652,000-95,556,000-127,379,000-167,743,000-218,618,000
Earnings
Aug 06, 2025

Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
URL
https://www.geron.com/
IPO date
Jul 31, 1996
Employees
107
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
76,994
32,386.92%
237
-60.23%
596
-57.21%
Cost of revenue
250,726
317,921
140,014
Unusual Expense (Income)
NOPBT
(173,732)
(317,684)
(139,418)
NOPBT Margin
Operating Taxes
(868)
Tax Rate
NOPAT
(173,732)
(317,684)
(138,550)
Net income
(174,572)
-5.19%
(184,127)
30.56%
(141,033)
16.60%
Dividends
Dividend yield
Proceeds from repurchase of equity
140,729
213,337
69,916
BB yield
-6.15%
-17.72%
-7.59%
Debt
Debt current
1,948
47,842
21,870
Long-term debt
7,772
42,012
38,479
Deferred revenue
Other long-term liabilities
220,631
Net debt
(396,846)
(287,143)
(112,761)
Cash flow
Cash from operating activities
(218,618)
(167,743)
(127,379)
CAPEX
(680)
(830)
(431)
Cash from investing activities
(106,004)
(180,322)
62,067
Cash from financing activities
334,372
362,021
87,264
FCF
(173,190)
(321,624)
(133,966)
Balance
Cash
406,566
333,699
173,110
Long term investments
43,298
Excess cash
402,716
376,985
173,080
Stockholders' equity
(1,771,735)
(1,597,039)
(1,413,471)
Invested Capital
2,279,166
1,930,887
1,549,222
ROIC
ROCE
EV
Common stock shares outstanding
646,033
570,645
380,785
Price
3.54
67.77%
2.11
-12.81%
2.42
98.36%
Market cap
2,286,958
89.94%
1,204,062
30.66%
921,499
130.54%
EV
1,890,112
916,919
808,738
EBITDA
(172,511)
(316,651)
(138,550)
EV/EBITDA
Interest
18,504
8,312
6,882
Interest/NOPBT